Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.

被引：4
|
作者：
Xia, Yongxiang
Wang, Ping
Pu, Liyong
Qian, Xiaofeng
Cheng, Feng
Wang, Ke
Zhang, Chuanyong
Li, Donghua
Li, Xiangcheng
Zhang, Feng
Zhao, Jie
Li, Si
Xi, Wenjing
Wang, Xuehao
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Hepatobiliary Ctr, Nanjing, Peoples R China
[2] Jiangsu Simcere Diagnost Co Ltd, Nanjing Simcere Med Lab Sci Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Dept Med, Nanjing, Peoples R China
[3] Jiangsu Simcere Diagnost Co Ltd, Nanjing Simcere Med Lab Sci Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Bioinformat Dept, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4082
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of camrelizumab combined with apatinib in the treatment of advanced gastric cancer: Preliminary results from a multicenter, prospective study.
    He, Yifu
    Hu, Bing
    Liu, Ke
    Cheng, Xiaofei
    Cheng, Huaidong
    Chen, Mo
    Hu, Changlu
    Li, Chenghui
    Mei, Xinkuan
    Liu, Jianfeng
    Liu, Hu
    Wang, Gang
    Li, Hongxia
    Zhang, Dingqing
    Luo, Huiqin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [3] Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
    Mo, Yunyan
    Pan, Yufei
    Zhang, Bin
    Zhang, Jian
    Su, Yixin
    Liu, Zhengchun
    Luo, Meiqing
    Qin, Guanjie
    Kong, Xiangyun
    Zhang, Rongjun
    Pan, Yu
    Liang, Yi
    Wang, Defeng
    Wei, Yuejia
    Chen, Hengwei
    Jiang, Wei
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [4] Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.
    Wang, Wei-Hu
    Xing, Baocai
    Wang, Hongzhi
    Zhu, Xianggao
    Wang, Kun
    Zheng, Xuan
    Dong, Dezuo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.
    Ni, Jun
    Zhang, Xiaotong
    Pan, Ruili
    Wang, Hanping
    Si, Xiaoyan
    Cui, Xiaoxia
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study
    Cui, Yunlong
    Bao, Xu
    Yu, Ge
    Li, Huikai
    Fang, Feng
    Li, Qiang
    Zhang, Wei
    Wu, Qiang
    Chen, Lu
    Liu, Chen
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)
    Liao, M.
    Yang, Y.
    Jiang, H.
    Huang, J.
    Liu, C.
    Yang, Y.
    Xie, K.
    Luo, X.
    Zhou, J.
    Wang, X.
    Wu, H.
    Zeng, Y.
    Li, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S664 - S665
  • [8] Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
    Yuan, Guosheng
    Cheng, Xiao
    Li, Qi
    Zang, Mengya
    Huang, Wei
    Fan, Wenzhe
    Wu, Tao
    Ruan, Jian
    Dai, Wencong
    Yu, Wenxuan
    Chen, Mian
    Guo, Yabing
    Hu, Xiaoyun
    Chen, Jinzhang
    ONCOTARGETS AND THERAPY, 2020, 13 : 12683 - 12693
  • [9] A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage
    Zhou, Jian
    Fan, Jia
    Gu, Fang-Ming
    Li, Tao
    Bai, Dou-Sheng
    Sun, Hui-Chuan
    Wang, Zheng
    Qiu, Shuang-Jian
    Ye, Qing-Hai
    Shi, Ying-Hong
    Gao, Qiang
    Wang, Xiao-Ying
    Yang, Xin-Rong
    Shi, Guo-Ming
    Peng, Yuan-Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study.
    Chen, Bin
    Lin, Run
    Huang, Yonghui
    Dai, Haitao
    Tang, Keyu
    Zhang, Guiyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345